The highest ESCAT score was for PIK3CA at level 2b, as clinical trial results of drugs targeting this pathway have demonstrated a signal of increased radiological response rate without data showing a meaningful overall survival benefit [38].The remainder were classed as level 3 (12/15), defined as demonstrating clinical benefit in other tumour types or in similar variants, or level 4a (2/15), defined as actionability of target predicted in preclinical in vitro or in vivo models. Here, PIK3CA is linked to neoplasm.